Wake Forest University Health Sciences Rövid összefoglaló This phase II trial studies ciprofloxacin compared to an inactive treatment placebo in diagnosing prostate cancer in patients undergoing removal of prostate cells or tissues for examination biopsy. Ciprofloxacin is an antibiotic, a type of drug used to treat infections caused by bacteria.
Giving ciprofloxacin to patients undergoing a prostate biopsy may help to lower abnormal prostate-specific antigen PSA levels caused by bacterial infection of the prostate gland and may or may not affect the detection rate of prostate cancer. To determine the non-inferiority of the rate of detection of prostate cancer in men with decreased serum PSA values treated with placebo compared to ciprofloxacin prior to prostate biopsy.
Prostate size normal values compare the change in PSA from randomization to biopsy in men treated with ciprofloxacin versus those prostate size normal values with placebo. To determine if benign prostatic hyperplasia BPH or erectile dysfunction are associated with abnormal PSA or prostatic inflammation reported in the biopsy specimen.
To determine the correlation between change in PSA from randomization to biopsy and urinalysis pre- and post-ciprofloxacin versus placebo. To determine the correlation between change in PSA and prostate massage pre- and post-ciprofloxacin versus placebo.
To determine the qualitative and quantitative difference in flora ciprofloxacin resistant organisms obtained from rectal swab pre- and post- two week course of ciprofloxacin vs. To correlate urinary, prostate massage or rectal swab findings to pathology findings including cancer, inflammation, prostatic intra-epithelial neoplasia PINatypical acinar proliferation ASAP or other findings at the end of the study.